reports
- Martin Huseby Karlsen
PDS Biotech Provides Business Update and Reports First Quarter 2024 Fi...
PDS Biotech Provides Business Update and Reports First Quarter 2024 Financial Results Provided Positive, Updated Data from Phase 2 VERSATILE-002 Clinical Trial with Versamune® HPV in Combination with KEYTRUDA® in Recurrent or Metastatic Head and Neck Cancer Expanded Global Intellectual Property Surrounding Versamune® Platform PRINCETON, N.J., May 15, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of in...
- Jonathan Moreland
CNMD CONMED CORPORATION
HWBK HAWTHORN BANCSHARES
EFR ENERGY FUELS
ZOM ZOMEDICA PHARMACEUTICALS CORP
EYE NATIONAL VISION HOLDINGS
CDLX CARDLYTICS INC
ISDR ISSUER DIRECT CORP.
FSK FS KKR CAPITAL CORP
GO GROCERY OUTLET HOLDING
FNWB FIRST NORTHWEST BANCORP
FOUR SHIFT4 PAYMENTS
HQL INC.
TLS TEKLA LIFE SCIENCES INVESTORS
TMCI TELOS
FLYW TREACE MED CONCEPTS INC
BGS FLYWIRE CORP
DCGO B&G FOODS
BHVN INC.
GRNT DOCGO INC
VSTS_w BIOHAVEN LTD
BHRB GRANITE RIDGE RESOURCES INC
VESTIS CORPORATION
BURKE HERBERT FINANCIAL SERVICES CORP
- Jonathan Moreland
SHEN SHENANDOAH TELECOMMUNICATIONS COMPANY
SAIA SAIA INC.
RYI RYERSON HOLDING CORPORATION
RM REGIONAL MANAGEMENT CORP
RHP RYMAN HOSPITALITY PROPERTIES INC.
PENN PENN NATIONAL GAMING INC.
LTRX LANTRONIX INC.
KMPR KEMPER CORPORATION
HUBB HUBBELL INCORPORATED CLASS B
HOO HERBALIFE NUTRITION LTD.
FFIN FIRST FINANCIAL BANKSHARES INC
CTRN CITI TRENDS INC.
CNMD CONMED CORPORATION
AXS AXIS CAPITAL HOLDINGS LIMITED
AMH AMERICAN HOMES 4 RENT CLASS A
AIN ALBANY INTERNATIONAL CORP. CLASS A
HWBK HAWTHORN BANCSHARES
EFR ENERGY FUELS
SABR SABRE CORP.
ALPN ALPINE SELECT AG
HTLD HEARTLAND EXPRESS INC.
MAC MACERICH COMPANY
HI HILLENBRAND INC.
GLO CLOUGH GLOBAL OPPORTUNITIES FUND
WDFC WD-40 COMPANY
PK PARK HOTELS & RESORTS INC.
CRVS CORVUS PHARMACEUTICALS
MAV PIONEER MUNICIPAL HIGH INCOME ADVANTAGE TRUST
MHI PIONEER MUNICIPAL HIGH INCOME TRUST
EAF GRAFTECH INTERNATIONAL
FRAF FRANKLIN FINANCIAL SERVICES CO.
BBDC BARINGS BDC INC.
GH GUARDANT HEALTH
MCFT MASTERCRAFT BOAT HOLDINGS
HQL TEKLA LIFE SCIENCES INVESTORS
CZR CAESARS ENTERTAINMENT INC
WSC WILLSCOT MOBILE MINI HOLDINGS CORP
PSTV PLUS THERAPEUTICS INC
CTOS CUSTOM TRUCK ONE SOURCE
TBBK INC.
MEGI THE BANCORP
NPCT INC.
RXO_w MAINSTAY CBRE GBL INFRASTRUCTURE MEGATRENDS FD
BYON NUVEEN CORE PLUS IMPACT FD
VSTS_w RXO INC
NBBK BEYON 3D LTD
ASGI VESTIS CORPORATION
EYPT NB BANCORP INC.
DBD ABERDEEN STANDARD GLOBAL INFRASTRUCTURE INCOME FUND
EYEPOINT PHARMACEUTICALS
INC.
DIEBOLD NIXDORF INCORPORATED
- Sid Rajeev
New Report: Contango Ore's Strategic Gold Mining Acquisition and Its M...
We are excited to share our latest equity research report on Contango Ore, Inc. (CTGO). In this report, we explore CTGO's recent acquisition of HighGold Mining, a move poised to significantly enhance their portfolio. This all-share deal, valued at $37 million, not only adds the high-grade Johnson Tract project in Alaska to CTGO's assets but also positions the company for accelerated growth and cost-effective production.
PDS Biotech VERSATILE-002 Phase 2 Clinical Trial Meets Primary Study E...
PDS Biotech VERSATILE-002 Phase 2 Clinical Trial Meets Primary Study Endpoints in First Line Recurrent/Metastatic HPV16-Positive Head and Neck Cancer 30 month median overall survival (OS); median OS independent of patient CPS score ORR 34% (CPS≥1); 48% (CPS≥20) Phase 3 registrational trial planned to initiate in 2024 PRINCETON, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious dis...
PDS Biotech to Participate in Upcoming May 2024 Investor Conferences
PDS Biotech to Participate in Upcoming May 2024 Investor Conferences PRINCETON, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, today announced that the Company will participate in two upcoming investor conferences taking place in May 2024. Details are as follows: The Citizens JMP Life Sciences ConferenceEvent: Company presentation and 1:1 meetingsPresentation Da...
- Jay Kornreich
- Richard Anderson
- Sydnie Rohme
PDS Biotech to Announce First Quarter 2024 Financial Results on May 15...
PDS Biotech to Announce First Quarter 2024 Financial Results on May 15, 2024 PRINCETON, N.J., May 07, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, today announced that the Company will report financial results for the first quarter of 2024 and provide a business update on Wednesday, May 15, 2024, before the market opens. The press release will be available in the Investor Re...
Hawthorn Bancshares Inc: 1 director
A director at Hawthorn Bancshares Inc bought 15,000 shares at 19.626USD and the significance rating of the trade was 58/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two yea...
- Jonathan Moreland
SAIA SAIA INC.
RYI RYERSON HOLDING CORPORATION
LTRX LANTRONIX INC.
HXL HEXCEL CORPORATION
HOO HERBALIFE NUTRITION LTD.
AIN ALBANY INTERNATIONAL CORP. CLASS A
HWBK HAWTHORN BANCSHARES
HI HILLENBRAND INC.
GLO CLOUGH GLOBAL OPPORTUNITIES FUND
EAF GRAFTECH INTERNATIONAL
GH GUARDANT HEALTH
DNA GINKGO BIOWORKS HOLDINGS
TBBK INC.
RXO_w THE BANCORP
VSTS_w INC.
CFFI RXO INC
RENT VESTIS CORPORATION
C&F FINANCIAL CORPORATION
RENT THE RUNWAY INC
- Martin Huseby Karlsen
PDS Biotechnology Announces Details of Virtual KOL Event
PDS Biotechnology Announces Details of Virtual KOL Event Virtual Webinar Updated VERSATILE-002 Phase 2 Trial Results, Unmet Treatment Needs in Advanced Head and Neck Cancer and Planned Triple Combination Trial to be held May 8, 2024 PRINCETON, N.J., May 03, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, today announced additional details of its virtual Key Opinion Leader (KO...
- Martin Huseby Karlsen
Consensus back in focus and tier-2 deepwater risk
With the start of the Q1 reporting season for Offshore Drilling, we sense increased investor attention on the risk to consensus. Although we like the investment case for its valuation in the out-years (2026), our estimates remain below consensus. We see potential for share price volatility as near-term consensus is revised lower, while investors gradually underwrite 2026 valuations. We also believe the gaps between contracts and increased idle-time risk for tier-2 deepwater rigs are not properly...
PDS Biotech Appoints Stephan Toutain as Chief Operating Officer
PDS Biotech Appoints Stephan Toutain as Chief Operating Officer Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) PRINCETON, N.J., May 02, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, today announced the appointment of Stephan Toutain, MS, MBA, as Chief Operating Officer (COO), effective as of May 1, 2024. “We are thrilled to welcome Stephan to the PDS Biot...
- Jonathan Moreland
FFIN FIRST FINANCIAL BANKSHARES INC
CINF CINCINNATI FINANCIAL CORPORATION
CHDN CHURCHILL DOWNS INCORPORATED
HWBK HAWTHORN BANCSHARES
NQP NUVEEN PENNSYLVANIA INVESTMENT QUALITY MUNICIPAL FUND INC.
NXJ NUVEEN NEW JERSEY DIVIDEND ADVANTAGE MUNICIPAL FUND
CLF CLIFFS NATURAL RESOURCES INC.
PWOD PENNS WOODS BANCORP INC.
PCB PACIFIC CITY FINANCIAL CORP
RYES PATRIOT MINEFINDERS INC.
HQL TEKLA LIFE SCIENCES INVESTORS
BHRB BURKE & HERBERT BANK & TR/VA
NPCT NUVEEN CORE PLUS IMPACT FD
GNLX GENELUX CORP
LSXMK LIBERTY SIRIUSXM GROUP
NBBK NB BANCORP INC.
ASGI ABERDEEN STANDARD GLOBAL INFRASTRUCTURE INCOME FUND
Beyond Cancer Selected to Present on the Clinical Development of Ultra...
Beyond Cancer Selected to Present on the Clinical Development of Ultra-High Concentration Nitric Oxide (UNO) Therapy at the 2024 American Society of Clinical Oncology Annual Meeting Company to host an event featuring key opinion leaders (KOLs) on Friday, May 31st in Chicago to highlight the ongoing clinical development of UNO HAMILTON, Bermuda, May 01, 2024 (GLOBE NEWSWIRE) -- Beyond Cancer, Ltd., a clinical stage biotechnology company developing ultra-high concentration nitric oxide (UNO) as an immunotherapeutic for solid tumors, today announced being selected to present on the clinica...
Transocean Ltd. Announces Consent Solicitation for 8.375% Senior Secur...
Transocean Ltd. Announces Consent Solicitation for 8.375% Senior Secured Notes due 2028 STEINHAUSEN, Switzerland, May 01, 2024 (GLOBE NEWSWIRE) -- Transocean Ltd. (NYSE: RIG) announced today that its wholly owned and indirect subsidiary, Transocean Titan Financing Limited (the “Company” and, together with Transocean Ltd., “Transocean”), is soliciting consents (“Consents” and, such solicitation being referred to herein as, the “Consent Solicitation”) from holders (the “Holders”) of its outstanding 8.375% Senior Secured Notes due 2028 (the “Notes”) as of 5:00 p.m. New York City time, on Apr...
Transocean Ltd. Reports First Quarter 2024 Results
Transocean Ltd. Reports First Quarter 2024 Results Three months ended March 31, December 31, Sequential 2024 2023 change(In millions, except per share amounts and backlog) Contract drilling revenues$763 $741 $22 Adjusted contract drilling revenues$767 $748 $19 Revenue efficiency(1) 92.9 % 97.0 % (4.1)% Operating and maintenance expense$523 $569 $(46) Net income (loss) attributable to controlling interest$98 $(104) $202 Diluted earnings (loss) per share$0.11 $(0.13) $0.24 Adjusted EBITDA$199 $122 $77 Adjusted EBITDA...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.